Dominik Escher
Founder at CDR-Life Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Philipp Spycher | M | - |
Araris Biotech AG
Araris Biotech AG Miscellaneous Commercial ServicesCommercial Services Araris Biotech AG engages in the development and research of an antibody-drug conjugate (ADC) linker technology. It focuses on the production of ADCs. Its linker platform enables the attachment of payload to off the shelf antibodies without the need of antibody engineering. The company was founded by Philipp Spycher, Isabella Attinger-Toller, and Dragan Grabulovski and is headquartered in Z?rich, Switzerland. | 5 years |
Francine Behar-Cohen | M | - |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | 16 years |
Dragan Grabulovski | M | - |
Araris Biotech AG
Araris Biotech AG Miscellaneous Commercial ServicesCommercial Services Araris Biotech AG engages in the development and research of an antibody-drug conjugate (ADC) linker technology. It focuses on the production of ADCs. Its linker platform enables the attachment of payload to off the shelf antibodies without the need of antibody engineering. The company was founded by Philipp Spycher, Isabella Attinger-Toller, and Dragan Grabulovski and is headquartered in Z?rich, Switzerland. | 5 years |
Christian Leisner | M | - |
CDR-Life Inc.
CDR-Life Inc. BiotechnologyHealth Technology CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017. | 7 years |
Reto Naef | M | - |
TOPADUR Pharma AG
TOPADUR Pharma AG Pharmaceuticals: MajorHealth Technology TOPADUR Pharma AG is a Swiss-based biotech company located in Schlieren. TOPADUR is a patient-oriented biotech company that aims to enhance the quality of life through cutting-edge research. The private company is developing a new class of compounds based on their innovative cgmp-enzyme regulation system, which corrects locally cgmp levels. These compounds target high medical needs and can be used to treat several ageing-related diseases resulting from insufficient local blood-circulation. The company was founded in 2015 by Reto Naef, who has been the CEO since then. | 9 years |
Patricia Zilliox | M | - |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | 8 years |
Michael Sidler | M | 55 |
University of Zurich
Araris Biotech AG
Araris Biotech AG Miscellaneous Commercial ServicesCommercial Services Araris Biotech AG engages in the development and research of an antibody-drug conjugate (ADC) linker technology. It focuses on the production of ADCs. Its linker platform enables the attachment of payload to off the shelf antibodies without the need of antibody engineering. The company was founded by Philipp Spycher, Isabella Attinger-Toller, and Dragan Grabulovski and is headquartered in Z?rich, Switzerland. | 13 years |
Gerald D. Cagle | M | 79 |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | 6 years |
Christian Ludin | M | - |
TOPADUR Pharma AG
TOPADUR Pharma AG Pharmaceuticals: MajorHealth Technology TOPADUR Pharma AG is a Swiss-based biotech company located in Schlieren. TOPADUR is a patient-oriented biotech company that aims to enhance the quality of life through cutting-edge research. The private company is developing a new class of compounds based on their innovative cgmp-enzyme regulation system, which corrects locally cgmp levels. These compounds target high medical needs and can be used to treat several ageing-related diseases resulting from insufficient local blood-circulation. The company was founded in 2015 by Reto Naef, who has been the CEO since then. | 5 years |
Ximing Ding | M | - |
Pureos Partners AG
Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | 6 years |
Roger Nitsch | M | 63 |
NovaGo Therapeutics AG
NovaGo Therapeutics AG Pharmaceuticals: MajorHealth Technology NovaGo Therapeutics AG is a biotechnology start-up company, which engages in the development and manufacture of human antibody products. It focuses on cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration. Its offering includes recombinant human monoclonal antibodies targeting the nerve outgrowth inhibitor Nogo-A. The company was founded by Martin E. Schwab and Roger M. Nitsch and is headquartered in Schlieren, Switzerland. | 9 years |
Isabella Attinger-Toller | M | - |
Araris Biotech AG
Araris Biotech AG Miscellaneous Commercial ServicesCommercial Services Araris Biotech AG engages in the development and research of an antibody-drug conjugate (ADC) linker technology. It focuses on the production of ADCs. Its linker platform enables the attachment of payload to off the shelf antibodies without the need of antibody engineering. The company was founded by Philipp Spycher, Isabella Attinger-Toller, and Dragan Grabulovski and is headquartered in Z?rich, Switzerland. | 5 years |
Martin E. Schwab | M | - |
NovaGo Therapeutics AG
NovaGo Therapeutics AG Pharmaceuticals: MajorHealth Technology NovaGo Therapeutics AG is a biotechnology start-up company, which engages in the development and manufacture of human antibody products. It focuses on cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration. Its offering includes recombinant human monoclonal antibodies targeting the nerve outgrowth inhibitor Nogo-A. The company was founded by Martin E. Schwab and Roger M. Nitsch and is headquartered in Schlieren, Switzerland. | - |
Ohad Hammer | M | - |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | - |
Jan Markus Grimm | M | - |
NovaGo Therapeutics AG
NovaGo Therapeutics AG Pharmaceuticals: MajorHealth Technology NovaGo Therapeutics AG is a biotechnology start-up company, which engages in the development and manufacture of human antibody products. It focuses on cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration. Its offering includes recombinant human monoclonal antibodies targeting the nerve outgrowth inhibitor Nogo-A. The company was founded by Martin E. Schwab and Roger M. Nitsch and is headquartered in Schlieren, Switzerland. | - |
Nicole Onetto | M | 71 |
CDR-Life Inc.
CDR-Life Inc. BiotechnologyHealth Technology CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017. | 2 years |
Dmitry Kuzmin | M | - |
Araris Biotech AG
Araris Biotech AG Miscellaneous Commercial ServicesCommercial Services Araris Biotech AG engages in the development and research of an antibody-drug conjugate (ADC) linker technology. It focuses on the production of ADCs. Its linker platform enables the attachment of payload to off the shelf antibodies without the need of antibody engineering. The company was founded by Philipp Spycher, Isabella Attinger-Toller, and Dragan Grabulovski and is headquartered in Z?rich, Switzerland. | 4 years |
Johannes Zanzinger | M | - |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | - |
Silvia Scherer | F | - |
TOPADUR Pharma AG
TOPADUR Pharma AG Pharmaceuticals: MajorHealth Technology TOPADUR Pharma AG is a Swiss-based biotech company located in Schlieren. TOPADUR is a patient-oriented biotech company that aims to enhance the quality of life through cutting-edge research. The private company is developing a new class of compounds based on their innovative cgmp-enzyme regulation system, which corrects locally cgmp levels. These compounds target high medical needs and can be used to treat several ageing-related diseases resulting from insufficient local blood-circulation. The company was founded in 2015 by Reto Naef, who has been the CEO since then. | 4 years |
Daniel Marks | M | - |
CDR-Life Inc.
CDR-Life Inc. BiotechnologyHealth Technology CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017. | - |
Eduardo Vianna | M | - |
NovaGo Therapeutics AG
NovaGo Therapeutics AG Pharmaceuticals: MajorHealth Technology NovaGo Therapeutics AG is a biotechnology start-up company, which engages in the development and manufacture of human antibody products. It focuses on cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration. Its offering includes recombinant human monoclonal antibodies targeting the nerve outgrowth inhibitor Nogo-A. The company was founded by Martin E. Schwab and Roger M. Nitsch and is headquartered in Schlieren, Switzerland. | 7 years |
Neena Kadaba | M | - |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | 4 years |
Pascal Brenneisen | M | - |
TOPADUR Pharma AG
TOPADUR Pharma AG Pharmaceuticals: MajorHealth Technology TOPADUR Pharma AG is a Swiss-based biotech company located in Schlieren. TOPADUR is a patient-oriented biotech company that aims to enhance the quality of life through cutting-edge research. The private company is developing a new class of compounds based on their innovative cgmp-enzyme regulation system, which corrects locally cgmp levels. These compounds target high medical needs and can be used to treat several ageing-related diseases resulting from insufficient local blood-circulation. The company was founded in 2015 by Reto Naef, who has been the CEO since then. | 9 years |
Hans Caspar von der Crone | M | 67 |
University of Zurich
| 27 years |
Andreas Plückthun | M | 65 |
University of Zurich
| 31 years |
Klaus Breiner | M | - |
Pureos Partners AG
Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | 7 years |
Arnd Kaltofen-Ehmann | M | 64 |
Araris Biotech AG
Araris Biotech AG Miscellaneous Commercial ServicesCommercial Services Araris Biotech AG engages in the development and research of an antibody-drug conjugate (ADC) linker technology. It focuses on the production of ADCs. Its linker platform enables the attachment of payload to off the shelf antibodies without the need of antibody engineering. The company was founded by Philipp Spycher, Isabella Attinger-Toller, and Dragan Grabulovski and is headquartered in Z?rich, Switzerland. | 4 years |
François Thomas | M | 66 |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | - |
Claudio Nessi | M | 56 |
CDR-Life Inc.
CDR-Life Inc. BiotechnologyHealth Technology CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017. | - |
Catherine Boule | F | - |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | - |
Rafaèle Elisabeth Tordjman | M | 54 |
CDR-Life Inc.
CDR-Life Inc. BiotechnologyHealth Technology CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017. | - |
Daniel Vasella | M | 70 |
TOPADUR Pharma AG
TOPADUR Pharma AG Pharmaceuticals: MajorHealth Technology TOPADUR Pharma AG is a Swiss-based biotech company located in Schlieren. TOPADUR is a patient-oriented biotech company that aims to enhance the quality of life through cutting-edge research. The private company is developing a new class of compounds based on their innovative cgmp-enzyme regulation system, which corrects locally cgmp levels. These compounds target high medical needs and can be used to treat several ageing-related diseases resulting from insufficient local blood-circulation. The company was founded in 2015 by Reto Naef, who has been the CEO since then. | 4 years |
Martin C. Münchbach | M | 54 |
Pureos Partners AG
Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | 7 years |
Paul Embrechts | M | 71 |
Swiss Federal Institute of Technology
| 35 years |
Hans Wehrli | M | 71 |
University of Zurich
| 31 years |
Günther Wess | M | - |
TOPADUR Pharma AG
TOPADUR Pharma AG Pharmaceuticals: MajorHealth Technology TOPADUR Pharma AG is a Swiss-based biotech company located in Schlieren. TOPADUR is a patient-oriented biotech company that aims to enhance the quality of life through cutting-edge research. The private company is developing a new class of compounds based on their innovative cgmp-enzyme regulation system, which corrects locally cgmp levels. These compounds target high medical needs and can be used to treat several ageing-related diseases resulting from insufficient local blood-circulation. The company was founded in 2015 by Reto Naef, who has been the CEO since then. | 9 years |
François Diederich | M | 72 |
Swiss Federal Institute of Technology
| 32 years |
Chahra Khaoua Epouse Louafi | F | 53 |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | - |
Gambillara Fonck Veronica | M | - |
Pureos Partners AG
Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | 2 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
André Schwaninger | M | - |
Swiss Federal Institute of Technology
| 5 years |
Teodoro D. Cocca | M | 51 |
University of Zurich
| 7 years |
Daniel Anders | M | 54 |
University of Zurich
| 7 years |
Judith Bischof | M | 50 |
University of Zurich
| 6 years |
Dominik Sauter | M | 61 |
Swiss Federal Institute of Technology
| 4 years |
Iris Bohnet Zürcher | M | 58 |
University of Zurich
| 5 years |
Rolf M. Zinkernagel | M | 80 |
University of Zurich
| 16 years |
Andreas Kinsky | M | 57 |
Swiss Federal Institute of Technology
| 4 years |
Thomas Meier | M | - |
University of Zurich
| 6 years |
Peter Kappeler | M | 55 |
Swiss Federal Institute of Technology
| 6 years |
Kurt Mäder | M | 62 |
Swiss Federal Institute of Technology
| 3 years |
Matthias P. Hünerwadel | M | 56 |
Swiss Federal Institute of Technology
| 7 years |
Philippe Weber | M | 59 |
University of Zurich
| 5 years |
Daniel Schmucki | M | 56 |
University of Zurich
| 6 years |
Reto Suter | M | 53 |
University of Zurich
| 8 years |
Rene Dittrich | M | 52 |
University of Zurich
| 6 years |
Patrick Frost | M | 56 |
University of Zurich
Swiss Federal Institute of Technology
| 8 years |
Cédric Perlet | M | - |
University of Zurich
| 7 years |
Marc Weber | M | 53 |
University of Zurich
| 7 years |
Thomas Roland Meier | M | 61 |
University of Zurich
| 4 years |
Thomas Schluep | M | - |
Swiss Federal Institute of Technology
| 5 years |
Michael Halbherr | M | 60 |
Swiss Federal Institute of Technology
| 5 years |
Seymur Tari | M | 55 |
Swiss Federal Institute of Technology
| 5 years |
Ji Han Xu | M | 71 |
Swiss Federal Institute of Technology
| 3 years |
Horst Rzepka | M | 57 |
University of Zurich
| 2 years |
Marc Deshusses | M | - |
Swiss Federal Institute of Technology
| 3 years |
Marcel Huber | M | - |
University of Zurich
| 6 years |
Ruedi Noser | M | 63 |
University of Zurich
| 4 years |
Tobias Foster | M | 49 |
University of Zurich
| 4 years |
Andreas Knecht | M | 55 |
University of Zurich
| 6 years |
Thierry Wolter | M | 59 |
Swiss Federal Institute of Technology
| 5 years |
Philipp Rickenbacher | M | 53 |
Swiss Federal Institute of Technology
| 5 years |
Sibyl Anwander Phan-huy | M | 61 |
Swiss Federal Institute of Technology
| 13 years |
Sita Monica Mazumder | M | 54 |
Swiss Federal Institute of Technology
| 5 years |
Christian Dominique Coppey | M | 59 |
Swiss Federal Institute of Technology
| 3 years |
Hans Brändle | M | 63 |
Swiss Federal Institute of Technology
| 14 years |
Anne-Marie M. Solari Bozzi-Altenburg | F | 56 |
University of Zurich
| 3 years |
Simon Moroney | M | 65 |
Swiss Federal Institute of Technology
| 3 years |
Jorn Gorlach | M | 62 |
Swiss Federal Institute of Technology
| 3 years |
Christian Hasler | M | - |
University of Zurich
| 5 years |
Paolo Buzzi | M | 63 |
Swiss Federal Institute of Technology
| 5 years |
Pierre C. Fazan | M | - |
Swiss Federal Institute of Technology
| 3 years |
Aron Braun | M | - |
Swiss Federal Institute of Technology
| 6 years |
Alexander Ernst | M | 57 |
Swiss Federal Institute of Technology
| 4 years |
Francesco Piazza | M | - |
Swiss Federal Institute of Technology
| 7 years |
Urs Wälchli | M | 57 |
University of Zurich
| 1 years |
Peter-Mark Vogel | M | 58 |
University of Zurich
| 4 years |
Frank Appel | M | 62 |
Swiss Federal Institute of Technology
| 3 years |
Marius Messerli | M | - |
Swiss Federal Institute of Technology
| 3 years |
Massimo Arnoldi | M | - |
Swiss Federal Institute of Technology
| 3 years |
André Chardonnereau | M | 59 |
Swiss Federal Institute of Technology
| 4 years |
Edouard Mercier | M | 57 |
Swiss Federal Institute of Technology
| 4 years |
Christine Binswanger | F | 60 |
Swiss Federal Institute of Technology
| 4 years |
Bernard Guillelmon | M | 57 |
Swiss Federal Institute of Technology
| 4 years |
Martin Paul Zehnder | M | 56 |
University of Zurich
| 3 years |
Catrina Luchsinger Gähwiler | M | - |
University of Zurich
| 3 years |
Georg Wohlwend | M | 61 |
University of Zurich
| 7 years |
Christian Wiesendanger | M | 60 |
University of Zurich
| 4 years |
Karl Stefan Mäder | M | 61 |
University of Zurich
| 3 years |
Markus C. Egloff | M | 63 |
Swiss Federal Institute of Technology
| 6 years |
Elisa Parisi-Capone | F | - |
University of Zurich
| 6 years |
Statistics
Country | Connections | % of total |
---|---|---|
Switzerland | 57 | 57.00% |
Germany | 35 | 35.00% |
France | 9 | 9.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Dominik Escher
- Personal Network